The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | First- and second-line treatment in DLBCL
Sridhar Chaganti, MD, PhD, MRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, gives a detailed overview of first- and second-line treatment in diffuse large B-cell lymphoma (DLBCL). Dr Chaganti first discusses frontline treatment, drawing focus on the use of R-CHOP, and briefly discusses the POLARIX study (NCT03274492) evaluating polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy in patients with DLBCL. Following this, Dr Chaganti discusses second-line treatment options for transplant-eligible patients and clinical trials in this area, including the ZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), and BELINDA (NCT03570892) trials. To conclude, Dr Chaganti discusses the unmet need in therapeutic options for transplant-ineligible patients, and the promise of novel agents including polatuzumab, bendamustine and rituximab (pola-BR) and tafasitamab. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
